Welcome to our dedicated page for BIOVAXYS TECHNOLOGY NEW news (Ticker: BVAXD), a resource for investors and traders seeking the latest updates and insights on BIOVAXYS TECHNOLOGY NEW stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BIOVAXYS TECHNOLOGY NEW's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BIOVAXYS TECHNOLOGY NEW's position in the market.
BioVaxys licensee SpayVac-for-Wildlife (BVAXD) reported peer-reviewed results from a one-year study in the Bavarian Forest showing a single dose of SpayVac reduced fertility to 11% vs 86% in controls in 47 free-ranging red deer monitored with camera traps, GPS collars and fecal progesterone. The liposome-delivered vaccine platform is licensed from BioVaxys and has now shown contraceptive efficacy across three deer species: fallow, white-tailed and red deer.
SpayVac-for-Wildlife has initiated the regulatory submission process for SpayVac targeting feral horses and free-ranging deer; the companies anticipate a potential royalty stream from sales.
